2024
Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2023
Lessons Learned from the Connecticut Response to COVID-19 in Nursing Homes during the First 2 Years of the Pandemic
Goodwin J, Harizaj A, Armstrong J, Maloney M, Ehrlich H, Leung V, Parikh S. Lessons Learned from the Connecticut Response to COVID-19 in Nursing Homes during the First 2 Years of the Pandemic. Journal Of The American Medical Directors Association 2023, 24: 1573-1578.e1. PMID: 37591486, DOI: 10.1016/j.jamda.2023.07.009.Peer-Reviewed Original ResearchNursing homesSARS-CoV-2-related deathLong-term care facilitiesNursing home residentsPublic healthConnecticut nursing homesPublic health crisisCOVID-19 casesHome residentsCOVID-19 surveillance systemCare facilitiesDeath burdenEarly pandemicLong-term care industryPandemic threatCOVID-19Connecticut DepartmentHealth crisisSurveillance systemInterventionPandemicHealthConnecticut populationHomeVaccineTracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial sectionRepeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria
Foy B, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson C, Kittelson J, Slater H, Bousema T, Da O, Coulidiaty A, Colt M, Wade M, Richards K, Some A, Dabire R, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. JMIR Research Protocols 2023, 12: e41197. PMID: 36939832, PMCID: PMC10132043, DOI: 10.2196/41197.Peer-Reviewed Original ResearchIvermectin mass drug administrationMass drug administrationINTERNATIONAL REGISTERED REPORT IDENTIFIERMalaria incidenceDrug AdministrationMalaria transmissionIntense seasonal malaria transmissionMalaria controlSecondary safety outcomesParallel-group trialSeasonal malaria transmissionAdverse event monitoringActive case surveillancePrimary outcomeControl IINonpregnant individualsPostintervention changesTrial interventionCare interventionsSafety outcomesCluster RandomizedSubset of individualsCase surveillanceConsecutive daysEntomological assessmentsArtemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
Nyangulu W, Mungwira R, Divala T, Nampota-Nkomba N, Nyirenda O, Buchwald A, Miller J, Earland D, Adams M, Plowe C, Taylor T, Mallewa J, van Oosterhout J, Parikh S, Laurens M, Laufer M. Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi. Malaria Journal 2023, 22: 32. PMID: 36707795, PMCID: PMC9881508, DOI: 10.1186/s12936-023-04466-w.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyLumefantrine levelsTreatment failureDrug-drug interactionsACPR ratesMalaria infectionTrimethoprim-sulfamethoxazolePCR correctionTreatment efficacyUndetectable HIV RNA viral loadEfavirenz-based antiretroviral therapyHIV RNA viral loadUncomplicated Plasmodium falciparum malariaHuman immunodeficiency virus (HIV) infectionArtemether-lumefantrine efficacyCohort of PWHEfavirenz-based regimensImmunodeficiency virus infectionRNA viral loadPlasmodium falciparum malariaMalaria treatment failurePopulation of adultsRandom-effects modelTherapeutic efficacy monitoringLumefantrine exposureStriving towards true equity in global health: A checklist for bilateral research partnerships
Hodson D, Etoundi Y, Parikh S, Boum Y. Striving towards true equity in global health: A checklist for bilateral research partnerships. PLOS Global Public Health 2023, 3: e0001418. PMID: 36963065, PMCID: PMC10021183, DOI: 10.1371/journal.pgph.0001418.Peer-Reviewed Original ResearchHigh-income countriesGlobal health scholarshipTeam membersHealth scholarshipLMIC institutionsGlobal health collaborationsGlobal healthMiddle-income countriesGlobal health researchGlobal health projectsGlobal health effortsLevel of trainingHealth collaborationHealth disciplinesGlobal health organizationsHealth effortsHealth researchHealth ProjectImprove equitySchool of MedicineGlobal health issueLMICsHealth issuesResearch partnershipsEquitable collaboration
2022
Moving towards malaria elimination with safer treatment for children with G6PD deficiency
Boum Y, Moukoko C, Parikh S. Moving towards malaria elimination with safer treatment for children with G6PD deficiency. The Lancet Infectious Diseases 2022, 23: 388-390. PMID: 36462525, DOI: 10.1016/s1473-3099(22)00724-1.Peer-Reviewed Original ResearchImpact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistanceClinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definitionThe Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis
Pfeffer DA, Satyagraha AW, Sadhewa A, Alam MS, Bancone G, Boum Y, Brito M, Cui L, Deng Z, Domingo GJ, He Y, Khan WA, Kibria MG, Lacerda M, Menard D, Monteiro W, Pal S, Parikh S, Roca-Feltrer A, Roh M, Sirdah MM, Wang D, Huang Q, Howes RE, Price RN, Ley B. Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis. Pathogens 2022, 11: 1045. PMID: 36145477, PMCID: PMC9502867, DOI: 10.3390/pathogens11091045.Peer-Reviewed Original ResearchSystematic reviewMedian activityDrug-induced haemolysisG6PD activityIndividual patient dataGenetic variantsGlucose-6-phosphate dehydrogenase enzyme activityStudy-specific definitionsMeta-AnalysisG6PD genotypeNormal activityPatient dataRelevant genetic variantsDifferent genetic variantsEnzymatic deficiencyGlucose-6-phosphate dehydrogenaseEnzyme activityVanua LavaAssociated enzyme activitiesG6PD mutationsViangchanDehydrogenase enzyme activityCurrent classificationTowards rainbow portable Cytophone with laser diodes for global disease diagnostics.
Jawad HJ, Yadem AC, Menyaev YA, Sarimollaoglu M, Armstrong JN, Watanabe F, Biris AS, Stumhofer JS, Nedosekin D, Suen JY, Parikh S, Zharov VP. Towards rainbow portable Cytophone with laser diodes for global disease diagnostics. Scientific Reports 2022, 12: 8671. PMID: 35606373, PMCID: PMC9126638, DOI: 10.1038/s41598-022-11452-w.Peer-Reviewed Original ResearchRepeatability and reproducibility of a handheld quantitative G6PD diagnostic
Ley B, Satyagraha A, Kibria MG, Armstrong J, Bancone G, Bei AK, Bizilj G, Brito M, Ding XC, Domingo GJ, von Fricken ME, Gornsawun G, Lam B, Menard D, Monteiro W, Ongarello S, Pal S, Panggalo LV, Parikh S, Pfeffer DA, Price RN, da Silva Orfano A, Wade M, Wojnarski M, Worachet K, Yar A, Alam MS, Howes RE. Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLOS Neglected Tropical Diseases 2022, 16: e0010174. PMID: 35176015, PMCID: PMC8853557, DOI: 10.1371/journal.pntd.0010174.Peer-Reviewed Original Research
2021
Repeat positive SARS-CoV-2 RNA testing in nursing home residents during the initial 9 months of the COVID-19 pandemic: an observational retrospective analysis
Armstrong JN, Campbell L, Rabatsky-her T, Leung V, Parikh S. Repeat positive SARS-CoV-2 RNA testing in nursing home residents during the initial 9 months of the COVID-19 pandemic: an observational retrospective analysis. The Lancet Regional Health - Americas 2021, 3: 100054. PMID: 34458887, PMCID: PMC8380052, DOI: 10.1016/j.lana.2021.100054.Peer-Reviewed Original ResearchRepeat positive testNursing home residentsPositive testHome residentsNursing homesSARS-CoV-2 RNA testingInitial positive test resultNegative RT-PCR testSARS-CoV-2 testingInitial positive testObservational retrospective analysisNursing home populationCOVID-19 vaccinationPositive test resultsYounger age groupsSARS-CoV-2 diagnosisSARS-CoV-2RT-PCR testPublic health guidanceInitial positive resultsNursing home casesMultiple comorbiditiesMedian timeProtective immunityRNA testingFour Human Cases of Eastern Equine Encephalitis in Connecticut, USA, during a Larger Regional Outbreak, 2019 - Volume 27, Number 8—August 2021 - Emerging Infectious Diseases journal - CDC
Brown SC, Cormier J, Tuan J, Lier AJ, McGuone D, Armstrong PM, Kaddouh F, Parikh S, Landry ML, Gobeske KT. Four Human Cases of Eastern Equine Encephalitis in Connecticut, USA, during a Larger Regional Outbreak, 2019 - Volume 27, Number 8—August 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2021, 27: 2042-2051. PMID: 34289334, PMCID: PMC8314835, DOI: 10.3201/eid2708.203730.Peer-Reviewed Original ResearchMapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa
Ehrlich HY, Bei AK, Weinberger DM, Warren JL, Parikh S. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2100685118. PMID: 34261791, PMCID: PMC8307356, DOI: 10.1073/pnas.2100685118.Peer-Reviewed Original ResearchDesign and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data
Jackson CL, Colborn K, Gao D, Rao S, Slater HC, Parikh S, Foy BD, Kittelson J. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data. Clinical Trials 2021, 18: 582-593. PMID: 34218684, PMCID: PMC8478782, DOI: 10.1177/17407745211028581.Peer-Reviewed Original ResearchConceptsIvermectin mass drug administrationMass drug administrationCluster-randomized trialControl of malariaCluster-randomized trial designDrug AdministrationCrossover designMixed effects modelsTrial designStudy designCluster-level analysisSmall sample sizeCluster-level summariesCluster-level interventionsParallel trialRisk of harmPrimary analysisMalariaAdministrationMixed-effects modelsTrialsLevel interventionsSample sizeAdditional evaluationParallel designSARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
Ehrlich HY, Harizaj A, Campbell L, Colt M, Yuan K, Rabatsky-Ehr T, Weinberger DM, Leung V, Niccolai LM, Parikh S. SARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2021, 27: 1288-1295. PMID: 33900171, PMCID: PMC8084507, DOI: 10.3201/eid2705.204936.Peer-Reviewed Original ResearchConceptsPoint prevalence surveyNursing homesInfectious Diseases journal - CDCPublic health surveillance dataInfection prevention measuresNursing home staffSARS-CoV-2Health surveillance dataPoisson regression modelsCommunity incidenceIncidence ratePrevalence surveyHome staffInfectious personsCoronavirus diseaseInfection statusOutbreak controlSurveillance dataPrevention measuresIncidenceRegression modelsDisease spreadStaffHomeResidentsEffectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021
Britton A, Slifka K, Edens C, Nanduri SA, M. S, Shang N, Harizaj A, Armstrong J, Xu K, Ehrlich HY, Soda E, Derado G, Verani JR, Schrag SJ, Jernigan JA, Leung VH, Parikh S. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 396-401. PMID: 33735160, PMCID: PMC7976620, DOI: 10.15585/mmwr.mm7011e3.Peer-Reviewed Original ResearchConceptsPfizer-BioNTech COVID-19 vaccineSkilled nursing facilitiesCOVID-19 vaccineLong-term care facilitiesSNF residentsNursing facilitiesCOVID-19 vaccine clinical trialsCOVID-19-associated morbidityEarly COVID-19 vaccinationSARS-CoV-2 infectionElectronic chart reviewVaccine effectiveness dataUnderlying medical conditionsVaccine clinical trialsCOVID-19 vaccinationPfizer-BioNTech vaccineSARS-CoV-2Long-term care programsStaff membersChart reviewFirst doseVaccination statusPartial vaccinationVaccine impactSecond dose
2020
Bordetella bronchiseptica: a rare cause of meningitis
Radcliffe C, Lier A, Doilicho N, Parikh S, Kaddouh F. Bordetella bronchiseptica: a rare cause of meningitis. BMC Infectious Diseases 2020, 20: 922. PMID: 33272197, PMCID: PMC7713019, DOI: 10.1186/s12879-020-05668-2.Peer-Reviewed Original ResearchConceptsRare causeBaseline neurological statusSetting of immunosuppressionOnset of symptomsCerebrospinal fluid leakTraumatic cerebrospinal fluid (CSF) leakHospital courseMechanical fallNeurological statusRecent surgeryRespiratory infectionsUlcerative colitisUnusual causeCase presentationWeDrain placementClinical conditionsFluid leakMeningitisAnimal contactMonoclonal antibodiesAnimal exposureAerobic coccobacillusB. bronchisepticaSystematic literature reviewCause